Clinical benefit in Phase-I trials of novel molecularly targeted agents: Does dose matter

S. Postel-Vinay, H. T. Arkenau, D. Olmos, J. Ang, J. Barriuso, S. Ashley, U. Banerji, J. De-Bono, I. Judson, S. Kaye

Résultats de recherche: Contribution à un journalArticleRevue par des pairs

79 Citations (Scopus)

Résumé

Phase-I trials traditionally involve dose-escalation to determine the maximal tolerated dose (MTD). With conventional chemotherapy, efficacy is generally deemed to be dose-dependent, but the same may not be applicable to molecularly targeted agents (MTAs). We analysed consecutive patients included in Phase-I trials at the Royal Marsden Hospital from 5 January 2005 to 6 June 2006. We considered only trials of monotherapy MTAs in which the MTD was defined. Three patient cohorts (A, B, and C) were identified according to the dose received as a percentage of the final trial MTD (0-33%, 34-65%, 66%). Potential efficacy was assessed using the non-progression rate (NPR), that is, complete/partial response or stable disease for at least 3 months by RECIST. A total of 135 patients having progressive disease before enrolment were analysed from 15 eligible trials. Median age was 57 years (20-86); male: female ratio was 1.8: 1. Cohort A, B, and C included 28 (21%), 22 (16%), and 85 (63%) patients; NPR at 3 and 6 months was 21% and 11% (A), 50% and 27% (B), 31% and 14% (C), respectively, P0.9. Median duration of non-progression (17 weeks; 95% CI13-22) was not correlated with the MTD level, P0.9. Our analysis suggests that the potential for clinical benefit is not confined to patients treated at doses close to the MTD in Phase-I trials of MTAs.

langue originaleAnglais
Pages (de - à)1373-1378
Nombre de pages6
journalBritish Journal of Cancer
Volume100
Numéro de publication9
Les DOIs
étatPublié - 5 mai 2009
Modification externeOui

Contient cette citation